Dr Allan Gamble and Professor Sarah Hook. Photo / Supplied
Dr Allan Gamble and Professor Sarah Hook. Photo / Supplied
A novel approach to combating antibiotic resistance in farm animals has won Otago Innovation's $100,000 Proof of Concept Grant competition for 2020.
Professor Sarah Hook and Dr Allan Gamble, from the School of Pharmacy, will use the prize to make chemically-modified antibiotics – known as prodrugs - which only activatein the presence of infection.
"If the animal is healthy the drug will just float round and do nothing. And because it's inactive it won't push the development of antibiotic resistance," Hook explained.
Antibiotic resistance is a growing problem in the livestock industry, both for animal health and human health, because the drug-resistant bacteria can be transferred to humans.
The issue stemmed from the fact that large numbers of healthy stock received the drug when a herd was dosed - because of one or more sick animals.
The Proof of Concept competition allowed Otago researchers to pitch an idea which could be turned into a commercial product.
It is run by Otago Innovation, a University of Otago company responsible for developing and commercialising the University's intellectual property.
In this year's contest, Hook and Gamble emerged as the winners from a record number of 32 entries.
Competition was fierce and at least eight of the other entrants are in further discussion with Otago Innovation about progressing their project toward commercial outcomes.
Otago Innovation CEO David Christensen said the record number of applications this year was very encouraging.
"The need to shortlist was a great challenge for us and the judging panel was highly complimentary of the 10 projects that were presented to them. The winners ticked all the boxes for the judges and have a real opportunity to make a difference in the animal health sector."
The winning team was already working closely with Otago Innovation.
"It's really exciting," Gamble said.
"As an academic, we are often focused on publishing. Working towards commercialisation of a product that we've developed is a new and exciting challenge I look forward to."
Talks were underway with pharmaceutical companies which specialised in animal remedies and veterinary medicines.
"At the moment we're working on model antibiotics, but we'll work with the companies and if they've got a particular product they want us to work on, we will start looking at that as well," Hook said.
Some "really nice early results" had given them confidence they were on the right track.
"We're developing this for animal health but we've got high expectations for it to move forward into human health as well," Gamble said.